Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model

Authors
Jo, Su KyoungAhn, Bo-EunChoi, Eun HyeKang, Ji EunAn, HyongginOh, Myoung-donRhie, Gi-eun
Issue Date
11-2월-2020
Publisher
ELSEVIER SCI LTD
Keywords
Anthrax vaccine; Passive immunization; Toxin neutralization assay; Survival rate
Citation
VACCINE, v.38, no.7, pp.1586 - 1588
Indexed
SCIE
SCOPUS
Journal Title
VACCINE
Volume
38
Number
7
Start Page
1586
End Page
1588
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/57671
DOI
10.1016/j.vaccine.2019.12.048
ISSN
0264-410X
Abstract
The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to AB mice and the mice were subsequently challenged with 100 x LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy. (C) 2019 Elsevier Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE